Anemia, hypertension, and myocardial dysfunction in end-stage renal disease

Seminars in Nephrology

Volumn 17, Issue 4, 1997, Pages 257-269

  Venkatesan, Jayanti ^a   Henrich, William L ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; ENALAPRIL; ERYTHROPOIETIN; LISINOPRIL; LOOP DIURETIC AGENT; METHYLDOPA; MINOXIDIL; PRAZOSIN; TERAZOSIN; VERAPAMIL;

ALGORITHM; ANEMIA; ASTHMA; AUTONOMIC DYSFUNCTION; BLOOD VOLUME; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DIALYSIS; ELECTROLYTE DISTURBANCE; ERYTHROPOIESIS; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERPARATHYROIDISM; HYPERTENSION; KIDNEY FAILURE; METABOLIC ACIDOSIS; ORTHOSTATIC HYPOTENSION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SEXUAL DYSFUNCTION; TREATMENT PLANNING;

ANEMIA; ANIMALS; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; RENAL REPLACEMENT THERAPY; SURVIVAL RATE; VENTRICULAR DYSFUNCTION;

EID: 0030855833     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (125)

1. Eschbach JW, Adamson JW: Guidelines for recombinent human erythropoietin therapy. Am J Kidney Dis 14:2-8, 1989 (suppl 2)
2. Ratcliff PJ, Ebert BL, Ferguson DJ: Regulation of erythropoietin gene. Nephrol Dial Transplant 10:18-27, 1995 (suppl 12)
3. Eschbach JW, Adamson JW: Recombinant human erythropoietin: Implications for Nephrology. Am J Kidney Dis 1:3-9, 1988
4. Bonner J, Alexion C, Muller Buhl U, et al: Recombinant human epo therapy in HD patients - dose determination and clinical response. Nephrol Dial Transplant 2:238-242, 1987
5. Harnett JD, Kent CM, Foley RN, et al: Cardiac function and hematocrit level. Am J Kidney Dis 25:53-57, 1995 (suppl 1)
6. Foley RN, Parfrey PS, Harnet JD, et al: Clinical and echocardiographic disease in patients starting ESRD therapy. KI 47:186-192, 1995
7. Kannel WB, Gorton T, Offult D: LVH by EKG: Prevalence, incidence and morbidity in the Framingham Study. Ann Intern Med 71:89-105, 1969
8. Kannel WB, Doyce JT, McNamara PM, et al: Precursors of sudden coronary death. Factors related to incidence of sudden death. Circulation 51:606-613, 1975
9. Richardson TQ, Greyton AC: Effects of polycythemia and anemia on cardiac output and other circulating factors. Am J Physiol 197:1167-1170, 1959
10. Duke M, Abelman WH: Hemodynamic response to chronic anemia. Circulation 39:503-515, 1969
11. Marsh JT, Brown WS, Wolcott D, et al: Electrophysiological indices of CNS in hemodialysis and CAPD. Kidney Int 30:957-963, 1986
12. Wolcott DL, Wellisch DK, Marsh JT, et al: Rela-tionship of dialysis modality and other factors to cognitive function in dialysis patients. Am J Kidney Dis 12:275-284, 1988
13. Rathner DP, Adams KM, Levin NW, et al: Effect of hemodialysis on the cognitive and sensory motor functioning of adult chronic HD patients. J Behav Med 6:291-311, 1983
14. Grotta JC, Mauer C, Pettigrew LC, et al: Red blood cell disorders and stroke. Stroke 17:811-817, 1986
15. Miyake T, King CK, Goldwasser E: Purification of human erythropoietin. J Biol Chem 252:5558-5564, 1977
16. Lui FK, Suggs S, Lin CH: Cloning and expression of human erythropoietin gene. Proc Natl Acad Sci USA 82:7580-7587, 1985
17. Powell JS, Berkner KL, Lebo RV, et al: Human erythropoietin gene: high level expression in stably transfected mammalian cells and chromosome localization. Proc Natl Acad Sci USA, 83:6465-6469, 1986
18. Caro J, Brown S, Miller O, et al: Erythropoietin levels in uremic nephric and anephric patients. J Lab Clin Med 93:449-458, 1979
19. Radtke HW, Clausoner A, Erbes PM, et al: Serum erythropoietin concentration in CRF: Relations to anemia and excretory function. Blood 54:877-884, 1979
20. Ersley AJ, Wilson J, Cole J: Erythropoietin titers in anemic non-uremic patients. J Lab Clin Med 109:429-433, 1987
21. Means RT Jr, Oison NJ, Krantz SB: Treatment of uremia of rheumatoid arthritis with recombinant human erythropoietin: Clinical and in vitro studies. Arthritis Rheum 32:638-642, 1985
22. Winearls CA, Oliva DO, Pippard MJ, et al: Effect of human erythropoietin derived from recombinant DNA on the anemia of patients maintained by chronic hemodialysis. Lancet 2:1175-1178, 1986
23. Eschbach JW, Egrie JC, Downing MR, et al: Correction of anemia of end stage renal disease with recombinant human erythropoietin. Results of combined phase I & II clinical trials. N Engl J Med 316:73-78, 1987
24. Eschbach JW, Abduhadi MH, Brown JK: Recombinant human erythropoietin in anemic patients with ESRD. Results of phase III multicenter trial. Ann Intern Med 111:992-1000, 1989
25. Silberberg JS, Racine N, Barre PE, et al: Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin. Can J Cardiol 6:1-4, 1990
26. Goldberg N, Lundin AP, Delano B, et al: Changes in left ventricular size, wall thickness and function in anemic patients treated with Recombinant human erythropoietin. Am Heart J 124:424-427, 1992
27. Low-Friedrich I, Grutzmacher P, Marz W, et al: Therapy with recombinant human erythropoietin reduces cardiac size and improves heart function in chronic hemodialysis patients. Am J Nephrol 11:54-60, 1991
28. Pascual J, Teruel JL, Moya JL, et al: Regression of left ventricular hypertrophy after partial correction of anemia and erythropoietin in patients on hemodialysis: A prospective study. Clin Nephrol 35:280-287, 1991
29. Longon GM, Zins B, Pannier B, et al: Vascular changes in hemodialysis patients in response to recombinant human erythropoietin. Kidney Int 36:878-882, 1989
30. Rosenlof K, Grohagen RC, Sorijavi A, et al: Beneficial effects of erythropoietin on hematological parameters, aerobic capacity and body fluid composition in patients on hemodialysis. J Intern Med 226:311-317, 1989
31. Grfitzmacher P, Scheurman E, Low I, et al: Correction of anemia by recombinant human erythropoietin. Effects on myocardial function. Contrib Nephrol 66:176-187, 1988
32. Loro I, Gruetzmacher P, Bergman M, et al: Echocardiographic findings in patients on maintenance hemodialysis substituted with recombinant human erythropoietin. Clin Nephrol 31:26-30, 1989
33. MacDougal IC, Lewis NP, Saunders MJ, et al: Long term cardio response effects of amelioration of renal anemia by erythropoietin. Lancet 35:489-493, 1990
34. Wolcot DL, Marsh JT, LaRue A, et al: Recombinant human erthyropoietin therapy may improve quality of life and cognitive function in clinical hemodialysis patients. Am J Kidney Dis 14:478-485, 1989
35. Nissenson AR: Recombinant human erythropoietin impact on brain and cognitive function, exercise tolerance, sexual potency and quality of life. Semin Nephrol 9:25-31, 1989 (suppl 2)
36. Eschbach JW: Erythropoietin - An overview. Am J Kidney Dis 18:3-9, 1991 (suppl 4)
37. Ware JE Jr: Methodology in behavioral and psychosocial cancer research. Conceptualizing disease impact and treatment outcomes. Cancer 53:2316-2323, 1987 (suppl)
38. Lundin AP: Quality of life: Subjective and objective improvement with erythropoietin therapy. Semin Nephrol 9:22-29, 1989 (suppl)
39. Evans RW, Rader B, Manningan DL: Quality of life of hemodialysis recipient treated with recombinant human erythropoietin. JAMA 263:825-830, 1990
40. Revicki DA, Brown RE, Feeny DH, et al: Health related quality of life associated with recombinant human erythropoietin Rx in predialysis chronic renal disease patients. Am J Kidney Dis 25:548-554, 1995
41. Powe NR, Griffiths RI, Watson AJ, et al: Effect of recombinant erythropoietin on hospital admissions, readmissions, length of stay and costs of dialysis patients. J Am Soc Nephrol 4:1455-1465, 1994
42. Roth D, Smith R, Schulman G: Effects of recombinant human erythropoietin on renal function in CRF predialysis patients. Am J Kidney Dis 24:777-784, 1994
43. Kampf D, Kahl A, Passlick J, et al: Single dose kinetics of recombinant human EPO after intravenous, subcutaneous and interperitoneal administration. Contrib Nephrol 76:106-111, 1989
44. Zucchelli P, Santon A, Zuccala A: Genesis and control of hypertension in hemodialysis patients. Semin Nephrol 8:163-168, 1988
45. Wiedman P: Pathogenesis of hypertension associated with chronic renal failure. Contrib Nephrol 41:47-65, 1989
46. DeWardener HE, MacGregor GA: Dahl's hypothesis that a saluretic substance may be responsible for sustained rise in arterial pressure: Its possible role in essential hypertension. Kidney Int 18:1-9, 1980
47. Converse RL, Jacobsen TN, Toto RD, et al: Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 327:1912-1918, 1992
48. Shichini M, Hiata Y, Ando K, et al: Plasma endothelial levels in hypertension and chronic renal failure. Hypertension 15:493-496, 1990
49. Koyama H, Tabata T, Nishzawa T, et al: Plasma endothelin levels in patients with uremia. Lancet 1:991-992, 1989
50. Suzuki N, Matsumoto H, Jiyandin T, et al: Endothelin-3 occurs in human plasma: Increased concentration in patients undergoing hemodialysis. Biochem Biophys Res Commun 169:809-815, 1990
51. Vallance P, Leone A, Calver A, et al: Accumulation of endogenous inhibitor of NO synthesis in CRF. Lancet 339:572-575, 1992
52. ++ and hypertension in CRF. Kidney Int 43:700-705, 1993
53. Gennain C, Nanin R, Gonnelli S: Hypertension and primary hyperparathyroidism: Role of adrenergic and RAA systems. Miner Electrolyte Metab 21:77-81, 1995
54. Schluter H, Quante C, Buchholz B, et al: Vasopressor factor partially purified from human parathyroid glands. Bichem Biophys Res Commun 188:323-329, 1992
55. Baumgart P, Walger P, Garnen S, et al: BP elevation in the night in chronic renal failure, hemodialysis and renal transplanation. Nephron 57:239-298, 1991
56. Charra B, Calemard E, Ruffet M, et al: Survival as an index of adequacy of dialysis. Kidney Int 41:1286-1291, 1992
57. Chazot C, Charra B, Laurant C, et al: Interdialytic BP control by long hemodialysis sessions. Nephrol Dial Transplant 10:831-837, 1995
58. Saldanha LF, Weiler EW, Goniek HC: Effect of continuous ambulatory peritoneal dialysis on blood pressure control. Am J Kidney Dis 21:184-188, 1993
59. Cannata JB, Isles CG, Briggs JD, et al: Comparison of BP control during HD and CAPD. Dialysis Transplant 12:674-677, 1986
60. Rave A, Villaneuve JP, Stone WJ, et al: Plasma binding and disposition of furosemide in nephrotic syndrome and in anemia. Clin Pharmacol Ther 24:199-207, 1978
61. Brater DC, Anderson SA, Brown CD: Response to furosemide in chronic renal insufficiency: Rationale for limited doses. Clin Pharmacol Dis 40:134-139, 1989
62. Inone M, Okajuma K, Iton K, et al: Mechanism of furosemide resistance in analbuminimic rats and hypoalbuminemic patients. Kidney Int 32:198-204, 1987
63. Leenen FHH, Hansen E: Antihypertensive drugs and cardiotrophic mechanisms. J Cardiovasc Pharmacol 17:550-57, 1991 (suppl 2)
64. Lardinois CK, Newman BL: Effects of antihypertensive drugs on serum lipids and lipoproteins. Arch Intern Med 148:1280-1288, 1988
65. Riegel W, Horl WH, Heldland A: Long term effects of nifedipine on carbohydrate and lipid metabolism in hypertensive hemodialyzed patients. Klin Worchensrhr 64:1124-1130, 1986
66. Maher JF: Pharmacokinetics in patients with renal failure. Clin Nephrol 21:39-46, 1984
67. Edgar B, Lindborg P, Regardh CG: Clinical pharmacokinetics of felodopine. Drugs 34:16-27, 1987 (suppl 3)
68. Levenson JA, Simon AC, Safar ME: Vasodilation of small and large arteries in hypertension. J Cardiovasc Pharmacol 7:5116-5120, 1985 (suppl 2)
69. Keane WF, Anderson S, Amell M, et al: Angiotensin converting enzyme inhibitors and progressive renal insufficiency. Ann Intern Med 3:503-516, 1989
70. Maschio G, Alberti D, Janin G, et al: Effect of ACE-inhibitor Benazepril on the progression of chronic renal insufficiency. N Engl J Med 334:939-945, 1996
71. Breyer JA, Hunsicker LG, Baur RP, et al: ACE-Inhibition in diabetic nephropathy. Kidney Int 45:5156-60, 1994 (suppl 45)
72. Lewis EJ, Hunsicker LA, Bair RP, et al: Effect of ACE-Inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462, 1993
73. Bosck M, Charlap S, Frishman WH: Angiotensin converting enzyme inhibitors in heart failure. Med Clin North Am 73:315-338, 1989
74. Donker AJ: Nephrotoxicity of Angiotensin converting enzyme inhibition. Kidney Im 31:5132-137, 1987 (suppl 20)
75. Koch-Weser J: The comeback of hydralazine (editorial). Am Heart J 95:1-3, 1978
76. Hanter HR, Metzer VN, Tindira CA, et al: Comparison of the effects of prazosin vs. propranolol on plasma lipoprotein lipids in patients receiving hemodialysis. Am J Med 80:82-89, 1986 (suppl 2A)
77. Isso JL, Santarosa PR, Larrabel PS, et al: Increased plasma norepinephrine and sympathetic nervous activity in essential hypertensive and uremic humans: Effects of clonidine. J Cardiovasc Pharmacol 10:5225-227, 1987 (suppl 12)
78. Hamett JD, Parfrey PS: LV dysfunction in dialysis subjects, in Henrich W (ed): Principles and Practices of Dialysis. Baltimore, MD, Williams & Wilkins 1994
79. Churchill DN, Taylor DW, Cook RJ: Canadian hemodialysis morbidity study. Am J Kidney Dis 19:214-234, 1992
80. Parfrey PS, Harnett JD, Griffiths SM, et al: Congestive heart failure in dialysis patients. Arch Intern Med 148:1519-1525, 1988
81. Harnett JD, Foley RN, Kent GM, et al: Congestive heart failure in dialysis patients. Prevalence, incidence, prognosis and risk factors. Kidney Int 47:884-890, 1995
82. Barnardi D, Bernini L, Cini G, et al: Asymmetric septal hypertrophy and sympathetic overactivity in normotensive hemodialyzed patients. Am Heart J 109:534-545, 1985
83. Huting J, Kramer W, Schutterle G, et al: Analysis of left ventricular changes associated with chronic hemodialysis. Nephron 49:284-290, 1988
84. Parfrey PS, Griffiths SM, et al: Clinical course of left ventricular hypertrophy in dialysis patients. Nephron 55:114-120, 1990
85. Chaignon M, Chen WT, Tarazi RC, et al: Effect of hemodialysis on blood volume distribution and cardiac output. Hypertension 3:327-332, 1981
86. Rambausek M, Ritz E, Man G, et al: Myocardial hypertrophy in rats with renal insufficiency. Kidney Int 28:775-782, 1985
87. Silberberg JS, Rahal DP, Patton DR, et al: Role of anemia in the pathogenesis of LVH in ESRD. Am J Cardiol 64:222-224, 1989
88. Anderson CB, Codd JR, Graft RA, et al: Cardiac failure and upper extremity AV dialysis fistula. Arch Intern Med 3:292-297, 1976
89. Heam DJ, Maher JF: Heart failure as a complication of hemodialysis fistula. Ann Intern Med 77:201-204, 1972
90. Bogin E, Massey SG, Harary I: Effect of PTH on rat heart cells. J Clin Invest 67:1215-1277, 1989
91. Hoste F, Drieke T, Larus S, et al: Cardiac interaction between PTH, β-adrenoceptor and verapamil in guinea pig in vitro. Clin Exp Pharmacol Physiol 7:377-385, 1980
92. Baczynski R, Massry SG, Kohan R, et al: Effect of PTH on myocardial energy metabolism in the heart. Kidney Int 27:718-725, 1985
93. Drieke T, Fleury J, Toure Y, et al: Effect of parathyroidectomy on LV function in hemodialysis patients. Lancet 1:112-114, 1980
94. McGonigle RJS, Fowler MB, Timmis AB, et al: Uremic cardiomyopathy: Potential role of vitamin D and PTH. Nephron 36:94-100, 1984
95. Feldman AM, Fivush B, Zahka KG, et al: Congestive cardiomyopathy in patients on CAPD. Am J Kidney Dis 11:76-79, 1988
96. Feldman AM, Fivush B, Zahka KG, et al: Congestive cardiomyopathy in patients on CAPD. Am J Kidney Dis 11:76-79, 1988
97. Mall G, Rambansek M, Neumeister A, et al: Myocardial interstitial fibrosis in experimental uremia-implications for cardiac compliance. Kidney Int 33:804-811, 1988
98. Lanyendorf R, Pirani CL: The heart in uremia. Am Heart J 33:282-307, 1947
99. Mall G, Huther W, Schneider J, et al: Diffuse intermyocardiocytic fibrosis in uremic patients. Nephrol Dial Transplant 5:39-44, 1990
100. Hess OM, Schneider J, Koch R, et al: Diastolic function and myocardial structure in patients with myocardial hypertrophy. Circulation 63:360-371, 1981
101. McLenachan JM, Henderson E, Dargie HJ: A possible mechanism of sudden death in LVH. J Hypertens 5:630-635, 1987 (suppl 5)
102. Maher ER, Young G, Smyth-Walsh B: Aortic and mitral valve calcification in patients with ESRD. Lancet 2:875-877, 1987
103. Nestico PF, Dapace NL, Kotler MN: Calcium-Phosphorus metabolism in dialysis patients with and without mitral annular calcium. Analysis of 30 patients. Am J Cardiol 51:497-500, 1983
104. Mitchell JH, Widenthal K, Johnson RL: Effects of acid base disturbances on cardiovascular and pulmonary function. Kidney Int 1:375-389, 1972
105. ++ interaction. Circ Res 65:894-902, 1989
106. Shapiro JI: Functional and metabolic response of isolated heart during acidosis: Effects of sodium bicarb and carbicarb. Am J Physiol 258:H1835-1839, 1990
107. Watters TA, Wendland MF, Parmley WW, et al: Factors influencing myocardial response to metabolic acidosis in isolated rat hearts. Am J Physiol 253:H1261-1270, 1987
108. Karins RG, Cohen JJ: Bicarbonate therapy for organic acidosis. The case for its continued use. Ann Intern Med 106:615-618, 1987
109. Ewing DJ, Winney R: Autonomie function in patients with CRF on intermittent hemodialysis. Nephron 15:424-429, 1975
110. Brecht HM, Ernst W, Koch KM: Plasma nonadren-alin levels in regular hemodialysis patients. Proc Eur Dial Transplant Assoc 12:281-289, 1975
111. Rascher W, Schong A, Krye VA, et al: Diminished vascular response to nonadrenaline in experimental chronic uremia. Kidney Int 21:20-25, 1982
112. Brodde DR, Daul A: α and β adrenergic receptor changes in patients on maintenance hemodialysis. Contrib Nephrol 41:99-107, 1987
113. Campese VM, Romoff MS, Levitan D, et al: Mechanism of autonomie nervous system dysfunction in uremia. Kidney Int 20:246-253, 1981
114. Baksi SN: Hypotensive action of parathyroid hormone in hypoparathyroid and hyperparathyroid rats. Hypertension 11:509-513, 1988
115. Kannel WB, Hjartland M, Castelli WP: Role of diabetes in CHF and the Framingham study. Am J Cardiol 34:29-34, 1974
116. Gotloid L, Servadio C: A possible case of beri beri heart failure in chronic hemodialysis patient. Nephron 14:293-298, 1975
117. Condon GM, DeVemejoul MC, Fabicin F: Association between aluminum accumulation and cardiac hypertrophy in hemodialysis patients. Am J Kidney Dis 13:75-83, 1989
118. Madsen BR, Alpert MA, Whiting RB, et al: Effect of hemodialysis on LV performance - analysis of echocardiographic subsets. Am J Nephrol 4:86-91, 1984
119. The CONSENSUS trial study group: Effects of enalopril on morbidity in severe CHF. N EngI J Med 316:1429-1435, 1987
120. Cohn JN, Archibald DG, Ziesche S: Effect of vasodilator therapy on mortaliby in chronic CHF. Results of Veterans Cooperative study. N Engl J Med 314:1547-1552, 1986
121. Mulrow CD, Mulrow JP, Linn WD, et al: Relative efficacy of vasodilator therapy in chronic CHF. JAMA 259:3422-3426, 1988
122. Jaeschke R, Oxman AD, Guyatt GH: To what extent do CHF patients in sinus rhythm benefit from digoxin therapy? A systemic overview and meta analysis. Am J Med 88:279-286, 1990
123. Delmez JA, Tirdira C, Grooms BP, et al: Parathyroid hormone suppression by intravenous 1,25 dihydroxy vitamin D. J Clin Invest 83:1349-1355, 1989
124. Charles DL, Dandai GA, Schwab SJ, et al: Oral calcitrol and calcium: Efficient treatment for uremic hyperparathyroidism. Kidney Int 34:840-844, 1988
125. Hebert MJ, Falardeau M, Pichelte V, et al: CAPD for patients with severe LV systolic dysfunction and ESRD. Am J Kidney Dis 25:761-768, 1995